- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02887937
Cystic Breast Masses by Contrast Enhanced Ultrasound (CEUS)
Qualitative and Quantitative Analysis of Cystic Breast Masses by Contrast Enhanced Ultrasound: Is Biopsy Necessary?
Study Overview
Detailed Description
Breast cancer is the most frequently diagnosed cancer in women. To diagnose these cancers, more than 1.6 million breast biopsies are performed each year in the United States, of which more than 60% have benign pathology. A large percentage of the benign biopsies show fibrocystic changes of the breast on histology. These biopsies can be avoided with better diagnostic tools identifying fibrocystic change. The Investigators propose that contrast enhanced ultrasound (CEUS) can aid in classifying and predicting if a cystic appearing breast mass is benign or malignant, and can be a supplemental imaging tool to mammography and conventional gray-scale ultrasound (US).
In standard clinical practice, if a breast mass appears to be cystic on gray-scale US but has some suspicious features which make it difficult to tell if the mass is truly cystic or solid, the decision making for follow-up versus biopsy is difficult. This leads to unnecessary biopsies (false positives) since many of these masses are a sequel of benign fibrosis and fibrocystic changes of the breast. CEUS may help classify these masses as cystic or solid. The central premise is based on the microbubble contrast agent used in CEUS, since it stays within the blood pool and will only show enhancement if a mass has solid components and has vascular flow.
The Investigators hypothesize that indeterminate cystic breast masses will not enhance on CEUS and will correlate with benign pathology. Quantitative CEUS parameters will also help classify these lesions. If this is the case, then in the future, the non-enhancing cystic breast masses will not need to be biopsied. This will decrease patient anxiety, unnecessary interventions, and save resources.
The investigators will investigate qualitative and quantitative parameters on CEUS in evaluating indeterminate cystic breast masses given BIRADS 4 and correlate these with histopathology obtained by biopsy and/or surgery. This data will help them to develop protocols to better distinguish between benign and malignant cystic appearing breast masses.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90033
- USC Department of Radiology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- >18 years of age
- recommended for an ultrasound guided biopsy due to breast mass detection
Exclusion Criteria:
- < 18 years of age
- prior history of breast cancer
- prior history of biopsy for that specific lesion
- any condition that would be a contraindication to the microbubble contrast agent used in CEUS such as pulmonary hypertension, 3cardiac shunts, and allergy to perflutren.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Breast Mass 4a-cystic
Contrast Enhanced UltraSound (CEUS) exams will be performed on a ultrasound machine for the 4a-cystic breast masses recommended for biopsy.
An intravenous line (IV) line will be inserted into the vein in the arm for the administration of the contrast agent, Definity (10 µL/kg) The patient will be asked to lie on a table for the 4DCT and unenhanced CT procedure and the images will be recorded.
For the contrast enhanced ultrasound, the contrast agent will be injected into the IV line.
The CEUS will be performed and the images will be recorded.
The contrast agent may be administered two to three more times as needed.
Scanning will then be repeated with 30 and 90 seconds delay after the IV contrast administration.
|
The contrast agent, Definity, 10 µL/kg, will be administered through an intravenous catheter placed in an antecubital vein.
Definity is an FDA approved contrast agent for cardiac studies and will be an off-label use in this study.
The agent will be injected as a single intravenous bolus followed by a 10 mL saline flush (0.9% NaCl).
Images will be recorded with clip function for 90 seconds following the administration of contrast while the probe is stabilized and minimal pressure applied.
During this time, qualitative evaluation of tumor enhancement will be observed, and the presence of contrast uptake within the tumor will be categorized.
Other Names:
|
Breast Mass 4a- non cystic
Contrast Enhanced UltraSound (CEUS) exams will be performed on a ultrasound machine for the 4a-non cystic breast masses recommended for biopsy.
An intravenous line (IV) line will be inserted into the vein in the arm for the administration of the contrast agent, Definity (10 µL/kg) The patient will be asked to lie on a table for the 4DCT and unenhanced CT procedure and the images will be recorded.
For the contrast enhanced ultrasound, the contrast agent will be injected into the IV line.
The CEUS will be performed and the images will be recorded.
The contrast agent may be administered two to three more times as needed.
Scanning will then be repeated with 30 and 90 seconds delay after the IV contrast administration..
|
The contrast agent, Definity, 10 µL/kg, will be administered through an intravenous catheter placed in an antecubital vein.
Definity is an FDA approved contrast agent for cardiac studies and will be an off-label use in this study.
The agent will be injected as a single intravenous bolus followed by a 10 mL saline flush (0.9% NaCl).
Images will be recorded with clip function for 90 seconds following the administration of contrast while the probe is stabilized and minimal pressure applied.
During this time, qualitative evaluation of tumor enhancement will be observed, and the presence of contrast uptake within the tumor will be categorized.
Other Names:
|
Breast Mass 4b
Contrast Enhanced UltraSound (CEUS) exams will be performed on a ultrasound machine for the 4b breast masses recommended for biopsy.
An intravenous line (IV) line will be inserted into the vein in the arm for the administration of the contrast agent, Definity (10 µL/kg) The patient will be asked to lie on a table for the 4DCT and unenhanced CT procedure and the images will be recorded.
For the contrast enhanced ultrasound, the contrast agent will be injected into the IV line.
The CEUS will be performed and the images will be recorded.
The contrast agent may be administered two to three more times as needed.
Scanning will then be repeated with 30 and 90 seconds delay after the IV contrast administration.
|
The contrast agent, Definity, 10 µL/kg, will be administered through an intravenous catheter placed in an antecubital vein.
Definity is an FDA approved contrast agent for cardiac studies and will be an off-label use in this study.
The agent will be injected as a single intravenous bolus followed by a 10 mL saline flush (0.9% NaCl).
Images will be recorded with clip function for 90 seconds following the administration of contrast while the probe is stabilized and minimal pressure applied.
During this time, qualitative evaluation of tumor enhancement will be observed, and the presence of contrast uptake within the tumor will be categorized.
Other Names:
|
Breast Mass 4c
Contrast Enhanced UltraSound (CEUS) exams will be performed on a ultrasound machine for the 4c breast masses recommended for biopsy.
An intravenous line (IV) line will be inserted into the vein in the arm for the administration of the contrast agent, Definity (10 µL/kg) The patient will be asked to lie on a table for the 4DCT and unenhanced CT procedure and the images will be recorded.
For the contrast enhanced ultrasound, the contrast agent will be injected into the IV line.
The CEUS will be performed and the images will be recorded.
The contrast agent may be administered two to three more times as needed.
Scanning will then be repeated with 30 and 90 seconds delay after the IV contrast administration.
|
The contrast agent, Definity, 10 µL/kg, will be administered through an intravenous catheter placed in an antecubital vein.
Definity is an FDA approved contrast agent for cardiac studies and will be an off-label use in this study.
The agent will be injected as a single intravenous bolus followed by a 10 mL saline flush (0.9% NaCl).
Images will be recorded with clip function for 90 seconds following the administration of contrast while the probe is stabilized and minimal pressure applied.
During this time, qualitative evaluation of tumor enhancement will be observed, and the presence of contrast uptake within the tumor will be categorized.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
lesions of malignant vs. benign biopsy histology
Time Frame: 0-2 months
|
The proportion of breast masses with presence of contrast uptake on CEUS will be calculated for lesions of malignant vs. benign biopsy histology, grouped by BIRADS categories
|
0-2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
classification rule with the CEUS parameters
Time Frame: 11-12 months
|
We will build a classification rule with the CEUS parameters and then assess whether this rule can classify benign or malignant BIRADS 4a cystic lesions correctly.
|
11-12 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Sandy C Lee, MD, University of Southern California
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HS-16-00483
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
Clinical Trials on Definity
-
University of VirginiaCompletedType 1 DiabetesUnited States
-
Lantheus Medical ImagingSyneos HealthCompletedCardiac DiseaseUnited States
-
Mayo ClinicLantheus Medical ImagingCompletedMyocardial Perfusion ImagingUnited States
-
Lantheus Medical ImagingCompletedCardiovascular DiseaseUnited States
-
E. Peden, MDThe Methodist Hospital Research Institute; Lantheus Medical ImagingCompleted
-
Thomas Jefferson UniversityRothman Institute Orthopaedics; Lantheus Medical ImagingCompletedChronic Exertional Compartment SyndromeUnited States
-
Thomas Jefferson UniversityAmerican Heart Association; Lantheus Medical ImagingCompletedHeart Failure | Blood Pressure | Cardiac Catheterization | Echocardiography | Heart VentriclesUnited States
-
University Health Network, TorontoLantheus Medical ImagingCompleted
-
University of VirginiaTerminatedInflammatory Bowel DiseaseUnited States
-
University of VirginiaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)UnknownContrast Induced Acute Kidney InjuryUnited States